TABLE 5.

Clinical features and outcomes of bloodstream infections due to DHA-1-related AmpC β-lactamase-producing K. pneumoniae isolates^a

Isolate no.	Age (yr)/sex	Underlying disease	Comorbid condition	Type or site of infection	Empirical therapy	Definitive therapy	Outcome
9	60/M	Colon cancer	Biliary invasion	Cholangitis	CAZ, AMK	IPM	Persistent fever after 3 days; treatment changed to imipenem, with cure
10	50/M	HCC	TACE	Unknown	CTX, AMK	IPM	Persistent fever after 4 days; treatment changed to imipenem, with cure
12	75/M	HCC	ICU, post-op. C-line	Peritonitis	CTX, AMK	IPM	Persistent fever after 4 days; treatment changed to imipenem, with cure
18	43/M	DM, LC	ICU care	Peritonitis	CTX, AMK	CTX, AMK	Death on day 3 of treatment
19	43/F	Brain tumor	Craniotomy, post-op.	Urinary tract infection	CIP	IPM	Persistent fever after 3 days; treatment changed to imipenem, with cure
21	65/M	LC	None	Peritonitis	CAZ	CAZ	Progression to infected right pleural effusion; death on day 16 of treatment
23	58/F	CBD stone	Post-EST	Cholangitis	CAZ	CAZ	Death on day 3 of treatment
28	54/M	Leukemia	Neutropenia, C-line	Unknown	ZOX, AMK	IPM	Persistent fever after 3 days; treatment changed to imipenem, with cure
36	54/F	LC	Foley catheter, C-line	Peritonitis	CTX, AMK	CTX, AMK	Death on day 3 of treatment
37	43/F	MCTD	ICU, Foley catheter, C-line	Pneumonia	CAZ, AMK	IPM, AMK	Persistent fever after 7 days; treatment changed to imipenem, but with death on day 29 of treatment
42	63/M	Pancreas cancer, DM	None	Cholangitis	CTX, AMK	IPM	Persistent fever after 3 days; treatment changed to imipenem, with cure
43	50/M	HCC	TACE	Liver abscess	CTX	IPM	Persistent fever after 5 days; treatment changed to imipenem, with drainage, cured
57	17/M	Aplastic anemia, BMT	Neutropenia, C-line	Unknown	ZOX, AMK	IPM, CIP	Persistent fever after 7 days; treatment changed to imipenem and ciprofloxacin, but with death on day 22 of treatment

^aAbbreviations: M, male; F, female; DM, diabetes mellitus; LC, liver cirrhosis; ICU, intensive care unit; C-line, central line; Post-op., postoperative state; MCTD, mixed connective tissue disease; HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; CBD, common bile duct; EST, endoscopic sphincterotomy; BMT, bone marrow transplantation; CTX, cefotaxime; CAZ, ceftazidime; ZOX, ceftizoxime; AMK, amikacin; CIP, ciprofloxacin; IPM, imipenem.